ReviewJournal of medicine and life
Development of new immunotherapy treatments in different cancer types.
Review in Journal of medicine and life. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012-2024).Frontiers in immunology · 2025Pooled it
- Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.Frontiers in immunology · 2023Pooled it
- Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach.Biomedicines · 2024Review
- Immunopeptidomics in the cancer immunotherapy era.Exploration of targeted anti-tumor therapy · 2024Review
- Brain Tumors: Development, Drug Resistance, and Sensitization - An Epigenetic Approach.Epigenetics · 2023Review
- Immunotherapy: an emerging modality to checkmate brain metastasis.Molecular cancer · 2023Review
- Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer.Biotechnology reports (Amsterdam, Netherlands) · 2023Article
- Effectiveness of immunological agents in non-small cell lung cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- The regulatory role of long non- coding RNAs as a novel controller of immune response against cancer cells.Molecular biology reports · 2022Article
- Article
- Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.Scientific reports · 2022Article
- Comprehensive comparison of theranostic nanoparticles in breast cancer.American journal of clinical and experimental immunology · 2022Review
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
- Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity.Cancers · 2020Review
- Spatially Resolved Analytical Chemistry in Intact, Living Tissues.Analytical chemistry · 2020Review
- Role of Immunotherapy in Advanced Gastroesophageal Cancer.Current oncology reports · 2020Review
- Irradiated Bladder Cancer Cells Expressing both GM-CSF and IL-21 versus Either GM-CSF or IL-21 Alone as Tumor Vaccine in a Mouse Xenograft Model.BioMed research international · 2019Article
- Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.Frontiers in immunology · 2018Review
- Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy.Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy involves the use of therapeutic modalities that determine a manipulation of the immune system by using immune agents such as cytokines, vaccines, cell therapies and humoral, transfection agents. Immunotherapy of cancer has to stimulate the host's anti-tumor response by increasing the effector cell number and the production of soluble mediators and decrease the host's suppressor mechanisms by inducing tumor killing environment and by modulating immune checkpoints. Immunotherapy seems to work better in more immunogenic tumors. Making a review of literature, the article presents the new immunologic treatments in cancers less presented in the latest conferences, cancers in which, immunotherapy is still under investigation. Bladder cancer was the first indication for which immunotherapy was used in 1970. A promising clinical research in bladder cancer is the use of immune checkpoint inhibitors. Although breast cancer is considered immunologically silent, several preclinical and clinical studies suggested that immunotherapy has the potential to improve the clinical outcomes for patients with breast cancer. Cervical cancer, brain cancer, head and neck cancer and colorectal and esophageal cancers are cancer types for which new immune-based cancer treatments are currently under development. Recent agents used in clinical trials will be described in before mentioned cancers.
Indexed as
Identifiers
27974927PMC5154307What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.